Publications by authors named "Laura Vertechy"

Claim this Profile
R
Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy.
Adriana Ionelia Apostol, Matteo Bruno, Carolina Maria Sassu, Serena Maria Boccia, Laura Vertechy

Int J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis.
Laura Vertechy, Raffaella Ergasti, Cristina Chiamenti, Davide Arrigo, Ilary Ruscito

Int J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Failure of early interval debulking surgery after standard neoadjuvant chemotherapy: May bevacizumab add something? A large retrospective study.
Raffaella Ergasti, Laura Vertechy, Ilary Ruscito, Serena Maria Boccia, Luigi Congedo

Eur J Surg Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of machine learning-based models to predict and explain the risk of ovarian cancer: a multicentric study on -mutated patients undergoing risk-reducing salpingo-oophorectomy.
Vera Loizzi, Maria Colomba Comes, Francesca Arezzo, Adriana Ionelia Apostol, Samantha Bove, Laura Vertechy

Front Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives.
Elena Giudice, Vanda Salutari, Carolina Maria Sassu, Viola Ghizzoni, Maria Vittoria Carbone, Laura Vertechy

Expert Rev Anticancer Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
Serena Maria Boccia, Carolina Maria Sassu, Raffaella Ergasti, Laura Vertechy, Adriana Ionelia Apostol

Drug Des Devel Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Margherita Turinetto, Andrea Ricotti, Claudia Marchetti, Carmela Pisano, Claudio Zamagni, Laura Vertechy

Cancers (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
Laura Vertechy, Serena Maria Boccia, Giordana Tiberi, Giacomo Avesani, Giacomo Corrado

Int J Gynecol Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study.
Claudia Marchetti, Martina Arcieri, Laura Vertechy, Raffaella Ergasti, Giorgia Russo

Eur J Surg Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond.
Francesca De Felice, Laura Vertechy, Elena Giudice, Raffaella Ergasti, Serena Boccia

J Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic.
Eleonora Palluzzi, Giacomo Corrado, Claudia Marchetti, Giulia Bolomini, Laura Vertechy

Int J Gynecol Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer.
Claudia Marchetti, Marco D'Indinosante, Carolina Bottoni, Chiara Di Ilio, Stefano Di Berardino, Laura Vertechy

Sci Rep· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-conization cervical stenosis treated with silicone catheter in microinvasive cervical cancer patient: A case report.
Angela Musella, Giusi Santangelo, Laura Vertechy, Anna Di Pinto, Carolina Maria Sassu

Int J Surg Case Rep· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening program in ovarian cancer: A logical step in clinical management? A meta-analysis.
Claudia Marchetti, Francesca De Felice, Giorgia Perniola, Francesca Lecce, Laura Vertechy

Curr Probl Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Angela Musella, Erlisa Bardhi, Claudia Marchetti, Laura Vertechy, Giusy Santangelo

Cancer Treat Rev· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience.
Claudia Marchetti, Angela Musella, Alessia Romito, Laura Vertechy, Innocenza Palaia

Oncology· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions.
Angela Musella, Laura Vertechy, Alessia Romito, Claudia Marchetti, Andrea Giannini

Chemotherapy· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study.
Pierluigi Benedetti Panici, Innocenza Palaia, Claudia Marchetti, Ilary Ruscito, Margherita Fischetti, Laura Vertechy

Oncology· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
Pierluigi Benedetti Panici, Claudia Marchetti, Laura Salerno, Angela Musella, Laura Vertechy

Ann Surg Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review.
Claudia Marchetti, Innocenza Palaia, Margherita Giorgini, Caterina De Medici, Roberta Iadarola, Laura Vertechy

Onco Targets Ther· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonabsorbable suture granuloma mimicking ovarian cancer recurrence at combined positron emission tomography/computed tomography evaluation: a case report.
Ludovica Imperiale, Claudia Marchetti, Laura Salerno, Roberta Iadarola, Carlotta Bracchi, Laura Vertechy

J Med Case Rep· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An unexpected complete remission of advanced intestinal-type vulvar adenocarcinoma after neoadjuvant chemotherapy: a case report and a literature review.
Angela Musella, Claudia Marchetti, Laura Salerno, Laura Vertechy, Roberta Iadarola

Case Rep Obstet Gynecol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis